Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Crossover Single Dose Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers Under Fasted Conditions

NCT05665283 is registered in ClinicalTrials.gov with Xcovery Holdings, Inc. as lead sponsor.

NCT NCT05665283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Crossover Single Dose Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers Under Fasted Conditions
Lead sponsor
Xcovery Holdings, Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 29, 2022
Completion date
August 8, 2023
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bioequivalency